Form D · Biotechnology
MalarVx, Inc.
Seattle, WA · CIK 0001559688
Offering snapshot reported Aug 25, 2026 · SEC filing
- Reported sold
- $125K Offering amount: $2.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Aug 8, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 25, 2026 | Initial | $125,000 | No comparison | 2 | SEC filing |
| Jun 21, 2017 | Amendment | $1,050,000 | $940,000vs Jan 30, 2015 | 21 | SEC filing |
| Nov 23, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 30, 2015 | Amendment | $110,000 | $0vs Jan 20, 2015 | 4 | SEC filing |
| Jan 20, 2015 | Initial | $110,000 | No comparison | 4 | SEC filing |
| Oct 18, 2012 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-595251
Promissory Note convertible into equity.
Source: Form D, filed Aug 25, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James N/A Davie | Director |
| Jodi N/A Herczeg | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1551 Eastlake Ave E Suite 100
Seattle, WA, 98102
Phone: (646) 522-2458
Seattle, WA, 98102
Phone: (646) 522-2458